Furthermore, the anti-PD-L1 therapy was associated with a reduced neutrophil-to-lymphocyte ratio, which is beneficial for the overall survival of renal cell cancer and non-small-cell lung carcinoma patients [68, 75]. The gene discussed is CD274; the disease is renal cell adenocarcinoma.